Pediatric Immunotherapy Discovery and Development Network (PI-DDN)(U01 - No Clinical Trial Allowed)

The summary for the Pediatric Immunotherapy Discovery and Development Network (PI-DDN)(U01 - No Clinical Trial Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Pediatric Immunotherapy Discovery and Development Network (PI-DDN)(U01 - No Clinical Trial Allowed): This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The overall goal of this FOA and the companion FOA, RFA-CA-19-012, is to establish a network of collaborating investigators to identify and advance research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation (B) that calls for the establishment of a pediatric immunotherapy translation science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system. This FOA solicits U01 applications for discrete research projects that address relevant research opportunities (e.g., mechanisms of immune evasion, model development, validation of a single target, etc.), whereas the companion FOA, RFA-CA-19-003, solicits multi-component U54 Center applications. Successful applicants from both FOAs will become members of the Pediatric Immunotherapy Discovery and Development Network (PI-DDN), which will address and implement the BRP recommendations.

Federal Grant Title:	Pediatric Immunotherapy Discovery and Development Network (PI-DDN)(U01 - No Clinical Trial Allowed)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-CA-19-004
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.353
CFDA Descriptions:	Information not provided
Current Application Deadline:	December 17th, 2018
Original Application Deadline:	December 17th, 2018
Posted Date:	August 13th, 2018
Creation Date:	August 13th, 2018
Archive Date:	January 22nd, 2019
Total Program Funding:	$3,000,000
Maximum Federal Grant Award:	$499,999
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	August 13th, 2018

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-19-004.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]

If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Data, Evaluation and Coordinating Center for: A Multilevel Approach to Connecting Underrep...; • Coordinating and Data Management Center for Acquired Resistance to Therapy Network (ARTNet...; • Communication and Decision Making for Individuals with Inherited Cancer Syndromes (U01 Cli...; • Participant Engagement and Cancer Genome Sequencing (PE-CGS): Coordinating Center (U24 Cli...; • Immuno-Oncology Translation Network (IOTN): Data Management and Resource-Sharing Center (D...; • Accelerating Colorectal Cancer Screening and follow-up through Implementation Science (ACC...; • Accelerating Colorectal Cancer Screening and follow-up through Implementation Science (ACC...
More Grants from the National Institutes of Health: • SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies...; • Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Al...; • Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional); • Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial No...; • Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimenta...